EXTENDED - TODAY ONLY: MarketBeat All Access For Just $399 $199 (save 50%)
×
QQQ   280.57 (-0.76%)
AAPL   141.17 (-2.11%)
MSFT   240.33 (-0.59%)
META   109.46 (+0.63%)
GOOGL   95.19 (-0.90%)
AMZN   92.42 (-1.63%)
TSLA   180.83 (-1.14%)
NVDA   156.39 (-1.19%)
NIO   10.50 (+3.75%)
BABA   79.86 (+5.25%)
AMD   73.39 (+0.27%)
T   19.01 (+1.01%)
MU   55.12 (-1.13%)
CGC   3.42 (+0.59%)
F   13.75 (+0.15%)
GE   85.66 (+0.22%)
DIS   94.69 (-1.05%)
AMC   7.43 (+1.36%)
PYPL   77.64 (-2.87%)
PFE   49.49 (-0.16%)
NFLX   280.96 (-0.07%)
QQQ   280.57 (-0.76%)
AAPL   141.17 (-2.11%)
MSFT   240.33 (-0.59%)
META   109.46 (+0.63%)
GOOGL   95.19 (-0.90%)
AMZN   92.42 (-1.63%)
TSLA   180.83 (-1.14%)
NVDA   156.39 (-1.19%)
NIO   10.50 (+3.75%)
BABA   79.86 (+5.25%)
AMD   73.39 (+0.27%)
T   19.01 (+1.01%)
MU   55.12 (-1.13%)
CGC   3.42 (+0.59%)
F   13.75 (+0.15%)
GE   85.66 (+0.22%)
DIS   94.69 (-1.05%)
AMC   7.43 (+1.36%)
PYPL   77.64 (-2.87%)
PFE   49.49 (-0.16%)
NFLX   280.96 (-0.07%)
QQQ   280.57 (-0.76%)
AAPL   141.17 (-2.11%)
MSFT   240.33 (-0.59%)
META   109.46 (+0.63%)
GOOGL   95.19 (-0.90%)
AMZN   92.42 (-1.63%)
TSLA   180.83 (-1.14%)
NVDA   156.39 (-1.19%)
NIO   10.50 (+3.75%)
BABA   79.86 (+5.25%)
AMD   73.39 (+0.27%)
T   19.01 (+1.01%)
MU   55.12 (-1.13%)
CGC   3.42 (+0.59%)
F   13.75 (+0.15%)
GE   85.66 (+0.22%)
DIS   94.69 (-1.05%)
AMC   7.43 (+1.36%)
PYPL   77.64 (-2.87%)
PFE   49.49 (-0.16%)
NFLX   280.96 (-0.07%)
QQQ   280.57 (-0.76%)
AAPL   141.17 (-2.11%)
MSFT   240.33 (-0.59%)
META   109.46 (+0.63%)
GOOGL   95.19 (-0.90%)
AMZN   92.42 (-1.63%)
TSLA   180.83 (-1.14%)
NVDA   156.39 (-1.19%)
NIO   10.50 (+3.75%)
BABA   79.86 (+5.25%)
AMD   73.39 (+0.27%)
T   19.01 (+1.01%)
MU   55.12 (-1.13%)
CGC   3.42 (+0.59%)
F   13.75 (+0.15%)
GE   85.66 (+0.22%)
DIS   94.69 (-1.05%)
AMC   7.43 (+1.36%)
PYPL   77.64 (-2.87%)
PFE   49.49 (-0.16%)
NFLX   280.96 (-0.07%)
NASDAQ:CDAK

Codiak BioSciences - CDAK Stock Forecast, Price & News

$0.70
-0.03 (-4.11%)
(As of 11/29/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.70
$0.75
50-Day Range
$0.61
$0.93
52-Week Range
$0.59
$15.08
Volume
79,367 shs
Average Volume
236,613 shs
Market Capitalization
$25.78 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.20

Codiak BioSciences MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
500.0% Upside
$4.20 Price Target
Short Interest
Healthy
1.03% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.69
Upright™ Environmental Score
News Sentiment
0.93mentions of Codiak BioSciences in the last 14 days
Based on 2 Articles This Week
Insider Trading
Acquiring Shares
$7.50 M Bought Last Quarter
Proj. Earnings Growth
Growing
From ($1.56) to ($0.98) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.78 out of 5 stars

Medical Sector

49th out of 1,038 stocks

Biological Products, Except Diagnostic Industry

6th out of 172 stocks

CDAK stock logo

About Codiak BioSciences (NASDAQ:CDAK) Stock

Codiak BioSciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing exosome-based therapeutics for the treatment of oncology, neuro-oncology, neurology, neuromuscular diseases, infectious diseases, and other diseases. Its lead product candidates are exoSTING and exoIL-12 exosome therapeutic candidates for the treatment of various solid tumors. The company is also developing exoASO-STAT6, an antisense oligonucleotide targeting the STAT6 transcription factor; and exoVACC, a modular platform for constructing precision vaccines. It has a collaboration agreement with the Jazz Pharmaceuticals Ireland Limited, Sarepta Therapeutics, Inc., Kayla Therapeutics S.A.S., Washington University, Ragon Institute of MGH, MIT, and Harvard. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Receive CDAK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Codiak BioSciences and its competitors with MarketBeat's FREE daily newsletter.

CDAK Stock News Headlines

Codiak Announces Pricing of $20 Million Public...
Codiak downgraded at Goldman Sachs after portfolio reset
See More Headlines
Receive CDAK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Codiak BioSciences and its competitors with MarketBeat's FREE daily newsletter.

CDAK Company Calendar

Last Earnings
11/04/2021
Today
11/29/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/09/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CDAK
Fax
N/A
Employees
102
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$4.20
High Stock Price Forecast
$7.00
Low Stock Price Forecast
$1.40
Forecasted Upside/Downside
+500.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

Net Income
$-37,160,000.00
Pretax Margin
-51.13%

Debt

Sales & Book Value

Annual Sales
$22.93 million
Book Value
$2.39 per share

Miscellaneous

Free Float
33,810,000
Market Cap
$25.78 million
Optionable
Not Optionable
Beta
3.41

Key Executives

  • Dr. Douglas Edward Williams Ph.D. (Age 64)
    Pres, CEO & Director
    Comp: $970.77k
  • Ms. Linda Cathavina Bain CPA (Age 52)
    CFO & Treasurer
    Comp: $602.54k
  • Dr. Sriram Sathyanarayanan Ph.D.Dr. Sriram Sathyanarayanan Ph.D. (Age 50)
    Chief Scientific Officer
    Comp: $502.17k
  • Dr. Konstantin Konstantinov Ph.D.Dr. Konstantin Konstantinov Ph.D. (Age 64)
    Chief Technology Officer
  • Mr. Christopher J. M. Taylor
    VP of Investor Relations & Corp. Communications
  • Ms. Yalonda Howze (Age 50)
    Exec. VP, Chief Legal Officer, Chief Compliance Officer & Corp. Sec.
  • Ms. Nicole BarnaMs. Nicole Barna (Age 48)
    Sr. VP of HR
  • Dr. David J. Mauro M.D. (Age 57)
    Ph.D., Chief Medical Officer
  • Dr. Benny Sorensen M.D.Dr. Benny Sorensen M.D. (Age 48)
    Ph.D., Member of Scientific Advisory Board & Consultant













CDAK Stock - Frequently Asked Questions

Should I buy or sell Codiak BioSciences stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Codiak BioSciences in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" CDAK shares.
View CDAK analyst ratings
or view top-rated stocks.

What is Codiak BioSciences' stock price forecast for 2023?

2 analysts have issued 1-year target prices for Codiak BioSciences' stock. Their CDAK share price forecasts range from $1.40 to $7.00. On average, they predict the company's share price to reach $4.20 in the next twelve months. This suggests a possible upside of 500.0% from the stock's current price.
View analysts price targets for CDAK
or view top-rated stocks among Wall Street analysts.

How have CDAK shares performed in 2022?

Codiak BioSciences' stock was trading at $11.14 at the beginning of 2022. Since then, CDAK shares have decreased by 93.7% and is now trading at $0.70.
View the best growth stocks for 2022 here
.

When is Codiak BioSciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 9th 2023.
View our CDAK earnings forecast
.

How were Codiak BioSciences' earnings last quarter?

Codiak BioSciences, Inc. (NASDAQ:CDAK) issued its quarterly earnings results on Thursday, November, 4th. The company reported ($0.97) EPS for the quarter, missing the consensus estimate of ($0.85) by $0.12. The company had revenue of $1.16 million for the quarter, compared to analysts' expectations of $2.87 million. Codiak BioSciences had a negative net margin of 51.13% and a negative trailing twelve-month return on equity of 109.51%.

When did Codiak BioSciences IPO?

(CDAK) raised $82 million in an initial public offering (IPO) on Wednesday, October 14th 2020. The company issued 5,500,000 shares at $14.00-$16.00 per share. Goldman Sachs, Evercore ISI, William Blair and Wedbush PacGrow acted as the underwriters for the IPO.

What is Codiak BioSciences' stock symbol?

Codiak BioSciences trades on the NASDAQ under the ticker symbol "CDAK."

Who are Codiak BioSciences' major shareholders?

Codiak BioSciences' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Flagship Pioneering Inc. (9.61%), Laurion Capital Management LP (5.47%), Armistice Capital LLC (2.72%), Alaska Permanent Fund Corp (4.33%), Vanguard Group Inc. (2.24%) and Ensign Peak Advisors Inc (1.41%). Insiders that own company stock include Benny Sorensen, Briggs Morrison, Konstantin Konstantinov, Nicole Barna, Sriram Sathyanarayanan and Venture Fund Viii LP Arch.
View institutional ownership trends
.

How do I buy shares of Codiak BioSciences?

Shares of CDAK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Codiak BioSciences' stock price today?

One share of CDAK stock can currently be purchased for approximately $0.70.

How much money does Codiak BioSciences make?

Codiak BioSciences (NASDAQ:CDAK) has a market capitalization of $25.78 million and generates $22.93 million in revenue each year. The company earns $-37,160,000.00 in net income (profit) each year or ($0.69) on an earnings per share basis.

How many employees does Codiak BioSciences have?

The company employs 102 workers across the globe.

How can I contact Codiak BioSciences?

The official website for the company is www.codiakbio.com. The company can be reached via phone at 617-949-4100 or via email at investorrelations@codiakbio.com.

This page (NASDAQ:CDAK) was last updated on 11/29/2022 by MarketBeat.com Staff